Indoco Remedies Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/gh77qgwevb0mwrf4pyhhsqqv.pdf

Key Takeaways


India Formulations: Acute Headwinds, Prescription Resilience

Aditi Panandikar: "I feel going forward, we must discuss India business more on a YTD or a MAT basis that is far better."

Europe: Delayed Approvals Clearing, Margin Story Building

Aditi Panandikar: "I'm not just looking at top line growth, but we should look at Europe over the next few years as growing at 20% plus in revenues. But more importantly, we should be watching the margins to improve on that business."

US Business: Commercial Revenue Replaces Milestones

Aditi Panandikar: "But I would be little cautious because the moment I say something to you guys, you expect the next month to do well. But US business is not like this."

API & Auric Site: Consolidation Year Before Ramp-Up

Aditi Panandikar: "I'm sure that in another 8 to 10 months, we will start getting high revenues from Auric site also and then we can really ramp up our API business."

Subsidiaries & Portfolio: OTC Momentum, FPP Build-Out

Aditi Panandikar: "I would say when it comes to Warren Remedies, let them breathe and grow sales."

Margins & Costs: Structural Lift, One-Time Drags


Guidance & Commitments

CommitmentSpecificsTimeline
Europe Q4 recoveryQ4 to be much better; Phase II MMP issues resolved, approval for higher batches, new sites coming inQ4 FY26
Europe revenue aspirationReach INR400-500 crFY28 or FY29
Europe growth rate20% plus revenue growth with improving marginsOver next few years
API ramp-up from AuricStart getting high revenues from Auric siteIn another 8-10 months
US businessReturn to INR300 crores at better margins than earlierDefinite visibility (undated)
OTC business growthNumber to go up safely by at least 30%Next year (FY27)
FPP new launchesAt least five new products from own portfolioFY27 (at various times)
Other expensesConfident to keep at INR150 cr on consolidated basisGoing forward
Debt reductionTotal consolidated debt down from INR920 cr to ~INR775-800 crBy end of March 2027
India business growthDouble-digit growth; not confident about 15%Going forward
India business vs IPMAble to do IPM levels or betterGoing forward

Key Metrics

MetricQ3 FY26
Consolidated net revenues₹434.3 cr, +7.9% YoY and -7.9% QoQ
Standalone net revenues₹389.6 cr, +6.8% YoY and -9% QoQ
Consolidated EBITDA to sales7.3% at ₹31.5 cr, vs 3% at ₹12 cr same quarter last year; vs 9.2% at ₹43.1 cr in Q2 FY26
Standalone EBITDA to net sales6.6% at ₹25.9 cr, vs 5.5% at ₹20.1 cr same quarter last year; vs 12.4% at ₹53.4 cr in Q2 FY26
Consolidated gross profit margin73%, improved from 68% over last 3 quarters; sequential improvement of around 300 bps
Domestic formulation revenues₹214.2 cr, vs ₹224.1 cr same quarter last year
International formulation revenues₹135.6 cr, +26.2% YoY
US business revenues₹34.1 cr, +21.6% YoY
Europe revenues₹48.5 cr, +36.9% YoY
Emerging markets revenues₹49.5 cr, +26.8% YoY
API business revenues₹34.4 cr, +24% YoY
OTC business revenues₹34 cr this quarter; ₹94 cr YTD
Warren Remedies growth+43% this quarter; +38% YTD
New introductions to India sales6.5% of India revenues
IQVIA prescription audit rank21st on MAT basis, with 10.86 cr prescriptions
Total consolidated debt~₹920 cr, comprising ₹700 cr in main business and ₹220 cr in WRPL; long-term debt at ₹590 cr
One-time costs (remediation, penalties, tech transfer)~₹35-40 cr in FY26 (per an analyst's math), including ~₹8-9 cr in penalties and remediation this quarter and ~₹20 cr annual tech transfer costs
Provision for new Labour Code₹7 cr